Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Short Interest Update

Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) was the target of a large drop in short interest in November. As of November 15th, there was short interest totalling 537,900 shares, a drop of 95.4% from the October 31st total of 11,790,000 shares. Currently, 7.5% of the company’s stock are short sold. Based on an average trading volume of 189,500 shares, the days-to-cover ratio is presently 2.8 days.

Citius Pharmaceuticals Stock Down 13.3 %

CTXR stock traded down $0.55 during trading on Wednesday, reaching $3.60. The stock had a trading volume of 416,582 shares, compared to its average volume of 100,311. The company has a market capitalization of $650.61 million, a price-to-earnings ratio of -15.00 and a beta of 1.66. Citius Pharmaceuticals has a one year low of $2.55 and a one year high of $26.75. The company’s 50 day moving average is $9.35 and its two-hundred day moving average is $14.20.

Hedge Funds Weigh In On Citius Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Vanguard Group Inc. raised its stake in shares of Citius Pharmaceuticals by 1.5% during the 1st quarter. Vanguard Group Inc. now owns 7,005,119 shares of the company’s stock worth $6,286,000 after purchasing an additional 104,889 shares during the period. Arkadios Wealth Advisors raised its position in Citius Pharmaceuticals by 50.0% in the second quarter. Arkadios Wealth Advisors now owns 150,000 shares of the company’s stock worth $88,000 after acquiring an additional 50,000 shares during the period. Point72 DIFC Ltd purchased a new position in Citius Pharmaceuticals in the second quarter valued at about $29,000. Cubist Systematic Strategies LLC bought a new position in shares of Citius Pharmaceuticals during the 2nd quarter valued at approximately $69,000. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Citius Pharmaceuticals during the 2nd quarter worth approximately $118,000. Hedge funds and other institutional investors own 16.88% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have recently weighed in on CTXR. HC Wainwright restated a “buy” rating and issued a $100.00 target price on shares of Citius Pharmaceuticals in a report on Tuesday, November 12th. D. Boral Capital restated a “hold” rating on shares of Citius Pharmaceuticals in a research note on Friday, November 22nd.

Citius Pharmaceuticals Company Profile

Citius Pharmaceuticals, Inc, a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome.